1st Annual conference report, Badalona, Spain

1st Annual conference report, Badalona, Spain

Share this post

Facebook
Twitter
LinkedIn
WhatsApp

The hybrid conference titled “Exploring the Frontiers of Cancer Immunotherapy: From Models to Breakthroughs” took place on June 1 and 2 at the Josep Carreras Leukaemia Research Institute in Badalona (Barcelona, Spain). The event attracted a total 100 in-person and 80 virtual participants on the first day, and 80 in-person and 50 virtual attendees on the second day.

The conference aimed to spotlight novel experimental models that bridge laboratory discoveries on immunotherapy research with clinical breakthroughs. The meeting provided a platform to explore a diverse array of experimental models encompassing in vitro, ex vivo, and in vivo approaches, which offer unique opportunities to delve into the intricate interplay between the immune system, tumour microenvironment, and immunotherapy interventions in a controlled and clinically relevant context.

The conference featured six distinguished invited speakers, including renowned figures in the field of immunotherapy such as David Barbie and Silvia Formenti. Their expertise illuminated the latest advancements and future directions in cancer immunotherapy. Moreover, the event showcased the work of other participating researchers through nine selected abstracts for oral presentation and sixteen for poster presentation. This provided a forum for attendees to exchange insights, discuss challenges, and explore innovative strategies for advancing immunotherapy research.

Notably, 49 attendees received travel support attend the conference, underscoring IMMUNO-model’s commitment to facilitating broader participation and knowledge exchange within the scientific community.

In summary, the 1st IMMUNO-model conference served as a dynamic platform for advancing the frontiers of cancer immunotherapy, bringing together diverse perspectives and expertise to drive meaningful progress in the fight against cancer.

Latest Updates

IMMUNO-model released Annual report for grant period 2, in which activities and achievements of IMMUNO-model are summarized.
Unraveling the contribution of post-transcriptional regulation in the cancer-immune cells cross-talk Jessica Dal ColAssistant Professor of Clinical PathologyDept. of Medicine, Surgery and Dentistry, University of Salerno, Italy View podcast here.
The Resistance, Chemotherapy, and Predictive Biomarkers (RCPB) group is seeking a highly qualified postdoctoral candidate to apply for an MSCA or AECC fellowship. Our research focuses on identifying mechanisms of resistance to...
IMMUNO-model Workshop: Harmonizing in vivo models of immunotherapy, past, present and future directions of WG 7-8 April 2025, Bergen, Norway Key dates Registration Travel expense reimbursement eligibility Speakers and abstract...
The third IMMUNO-model Annual Conference, “Modeling Immunotherapy for Cancer: Bridging Research to Clinical Application” will take place at University of Warsaw in Poland from 13-14th May 2025. The conference will...
The international conference “IMMUNO-model Second Annual Conference: From Pre-clinical Models to the Search for Biomarkers in Immuno-Oncology” was held in Bratislava from May 13th to 15th 2024. The conference was...

Join us

How to Participate

The COST Action IMMUNO-model welcomes research-active scientists working in the field.

How to Get Involved

  • Read the Project Description MoU;
  •  Inform the Main Proposer/Chair of your interest (email);
  • Apply to join your Working Groups of interest;
  • You will be informed by the working group leaders as soon as your application has been reviewed;
  • Please note, Management Committee nominations are carried out through the COST National Contact Points.

How to participate in an existing Action?

If you would like to join this COST Action please ensure that you read the guidance notes published on the COST website. You can find full documentation regarding general rules and guidelines for COST Actions at www.cost.eu/participate.

Subscribe to our newsletter